Journal
NATURE
Volume 553, Issue 7689, Pages 446-454Publisher
NATURE PORTFOLIO
DOI: 10.1038/nature25183
Keywords
-
Categories
Funding
- Yale SPORE in Lung Cancer [P50CA196530]
Ask authors/readers for more resources
Important advancements in the treatment of non-small cell lung cancer (NSCLC) have been achieved over the past two decades, increasing our understanding of the disease biology and mechanisms of tumour progression, and advancing early detection and multimodal care. The use of small molecule tyrosine kinase inhibitors and immunotherapy has led to unprecedented survival benefits in selected patients. However, the overall cure and survival rates for NSCLC remain low, particularly in metastatic disease. Therefore, continued research into new drugs and combination therapies is required to expand the clinical benefit to a broader patient population and to improve outcomes in NSCLC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available